In vivo therapeutic effects of affinity-improved-TCR engineered T-cells on HBV-related hepatocellular carcinoma

作者：Qi Liu, Ye Tian, Yanyan Li, Yanyan Li, Wei Zhang, Wenxuan Cai, Yaju Liu, Yuefei Ren, Zhaoduan Liang, Peipei Zhou, Yajing Zhang, Yifeng Bao, Yi Li, Yi Li · 发表于：Journal for ImmunoTherapy of Cancer · 年份：2020 · DOI：10.1136/jitc-2020-001748 · 被引用次数：44 · 研究领域：CAR-T cell therapy research、Hepatitis B Virus Studies、Cancer Immunotherapy and Biomarkers

Background In patients with hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC), virus-specific cytotoxic T lymphocytes (CTLs) fail to eliminate HCC cells expressing HBV antigens. As the expression of viral antigen in HBV-associated HCC may decrease to allow tumor to escape immune attacks, we hypothesized that an HBV surface antigen (HBsAg)-specific affinity-improved-T-cell receptor (TCR) will enable T cells to target HCC more effectively than corresponding wild-type-TCR. We also postulated that TCR promiscuity can be exploited to efficiently capture HBV variants that can hinder CTL-based therapeutics. Methods We applied flexi-panning to isolate affinity-improved TCRs binding to a variant antigen, the human leukocyte antigen (HLA)-A*02:01-restricted nonapeptide HBs 371-379 -ILSPFLPLL, from libraries constructed with a TCR cloned using the decapeptide HBs 370-379 -SIVSPFIPLL. The potency and safety of the affinity-improved-TCR engineered T-cells (Ai-TCR-T) were verified with potentially cross-reactive human and HBV-variant peptides, tumor and normal cells, and xenograft mouse models. Results Ai-TCR-T cells retained cognate HBV antigen specificity and recognized a wide range of HBV genotypic variants with improved sensitivity and cytotoxicity. Cell infusions produced complete elimination of HCC without recurrence in the xenograft mouse models. Elevated accumulation of CD8 + Ai-TCR-T cells in tumors correlated with tumor shrinkage. Conclusion The in vitro and in vivo ...